These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28025143)

  • 1. Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
    Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
    Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of [
    Lesniak WG; Mease RC; Chatterjee S; Kumar D; Lisok A; Wharram B; Kalagadda VR; Emens LA; Pomper MG; Nimmagadda S
    Mol Imaging; 2019; 18():1536012119852189. PubMed ID: 31187691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model.
    Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H
    Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-Based
    De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
    Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
    Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
    J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
    Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
    Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
    Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
    Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging.
    Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H
    Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-Specific Immuno-PET Tracer to Image PD-L1.
    Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
    Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
    Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
    Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
    Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Wang Y; Zhang Y; Chen Y; Wang S; Liu W; Liu Z; Hu M
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3161-3175. PubMed ID: 38713298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
    Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
    Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.